The non-alcoholic steatohepatitis treatment market size is expected to reach USD 90.97 billion by 2034, exhibiting a CAGR of 28.0% during 2024–2034.
The Non-Alcoholic Steatohepatitis (NASH) Treatment Market is focused on the treatment and management of NASH, a progressive liver disease characterized by inflammation and fat accumulation in the liver in individuals who do not consume excessive alcohol. NASH can lead to cirrhosis, liver failure, and an increased risk of liver cancer. As the global prevalence of obesity, type 2 diabetes, and metabolic syndrome increases, the demand for NASH treatments is rising. This market involves pharmaceutical therapies, including drugs in development, diagnostic tools, and lifestyle interventions.
Market Growth Drivers
- Increasing Prevalence of Obesity and Metabolic Diseases
- The global rise in obesity, type 2 diabetes, and metabolic syndrome significantly increases the number of individuals at risk for developing NASH. With an estimated 25-30% of the world’s population affected by fatty liver disease, NASH is a growing health concern.
- Rising Awareness of NASH
- As awareness of NASH increases, both among healthcare providers and patients, there is a growing demand for effective treatments and diagnostic tools. This is driving the market for NASH therapeutics.
- Advances in NASH Drug Development
- The development of targeted therapies aimed at managing NASH’s underlying mechanisms, such as fibrosis, inflammation, and lipid metabolism, is expected to revolutionize the treatment landscape. Multiple investigational therapies in late-stage trials are promising.
Key Companies in Non-alcoholic Steatohepatitis Treatment Market
- Intercept Pharmaceuticals, Inc.
- Galmed Pharmaceuticals Ltd
- Inventiva
- AbbVie Inc.
- Galectin Therapeutics Inc.
- Madrigal Pharmaceuticals Inc (Madrigal)
- NGM Biopharmaceuticals, Inc.
- Novo Nordisk A/S
- The Bristol-Myers Squibb Company
Download Free Sample PDF Copy of the Report:
Key Trends in the NASH Treatment Market
- Drug Development and Approvals
- Several novel drug classes, including peroxisome proliferator-activated receptor (PPAR) agonists, FXR agonists, acetyl-CoA carboxylase inhibitors, and GLP-1 receptor agonists, are being developed to treat NASH. Drugs targeting liver fibrosis and inflammation, such as Cenicriviroc and Obeticholic acid, are showing promising results.
- Combination Therapies
- Due to the complex nature of NASH, combination therapies targeting multiple disease pathways are being explored. For example, combining anti-fibrotic agents with anti-inflammatory or metabolic regulators offers hope for more effective treatment outcomes.
- Non-Invasive Diagnostics
- Advances in non-invasive diagnostic methods, including imaging technologies (such as elastography), biomarkers, and blood tests, are reducing the reliance on liver biopsies, making NASH diagnosis easier, quicker, and less risky.
𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬:
The research study includes segmental analysis that divides the market into distinct groups or segments based on common characteristics. With market segmentation, businesses can identify specific customer groups that are more likely to be interested in specific products or services. Also, it enables these businesses to focus their marketing efforts and resources more efficiently, leading to higher conversion rates and improved return on investment. Furthermore, segmentation analysis helps companies develop personalized products or services, which can result in increased customer loyalty and improved customer satisfaction.
By Drug Outlook (Revenue, USD Billion; 2020–2034)
- Vitamin E and Pioglitazone
- Obeticholic Acid (OCA)
- Lanifibranor
- Semaglutide
- Resmetirom
- Aramchol
- Cenicriviroc
- Other Drugs
By Disease Stage Outlook (Revenue, USD Billion; 2020–2034)
- NASH Stage F0
- NASH Stage F1
- NASH Stage F2
- NASH Stage F3
- NASH Stage F4
By Distribution Channel Outlook (Revenue, USD Billion; 2020–2034)
- Hospital Pharmacies
- Retail and Specialty Pharmacies
- Other Pharmacies
Non-alcoholic Steatohepatitis Treatment Market Developments
In March 2024, the FDA approved Rezdiffra (resmetirom) for adults with noncirrhotic NASH and moderate to advanced hepatic fibrosis to be used alongside diet and exercise.
In June 2023, Echosens, a leader in hepatic diagnostic technologies, partnered with Novo Nordisk A/S to enhance early detection of non-alcoholic steatohepatitis (NASH) and increase awareness among patients, healthcare professionals, and stakeholders. The collaboration aims to improve diagnostic approaches and educational outreach regarding NASH.
The Non-Alcoholic Steatohepatitis (NASH) treatment market is poised for significant growth, driven by an increasing global burden of metabolic diseases and advancing therapies targeting NASH’s complex pathophysiology. With ongoing innovations in drug development, combination therapies, and non-invasive diagnostic tools, the market is set to transform the way NASH is diagnosed, treated, and managed.